Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Celeris Therapeutics–Pace Ventures Enigma: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Pace Ventures Enigma 2022-02-10
Celeris Therapeutics–R42 Group: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor R42 Group 2022-02-10
Celeris Therapeutics–SEVERAL: investment, 202202 seed financing round $4.4m led by Pace Ventures Enigma + i&i Biotech Fund + Apex Ventures 2022-02-10
Haya Therapeutics–4See Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor 4See Ventures 2022-02-09
Haya Therapeutics–Apollo Health Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Apollo HV 2022-02-09
Haya Therapeutics–Bernina BioInvest: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Bernina BioInvest 2022-02-09
Haya Therapeutics–Broadview Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Broadview Ventures 2022-02-09
Haya Therapeutics–Humboldt Fund: investment, 202202 seed financing round extension totalling $5m incl new + lead investor Humboldt Fund 2022-02-09
Haya Therapeutics–Schroders: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Schroder Adveq 2022-02-09
Haya Therapeutics–SEVERAL: investment, 202202 seed financing round extension $5m led by new investor Humboldt Fund 2022-02-09
Haya Therapeutics–Viva Biotech: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Viva BioInnovator 2022-02-09
Lindis Blood Care–Brandenburg (govt): investment, 202202 follow-on financing round incl existing + co-lead investor Brandenburg Kapital 2022-02-09
Lindis Blood Care–High-Tech Gründerfonds: investment, 202202 follow-on financing round incl existing + co-lead investor HTGF 2022-02-09
Lindis Blood Care–MC Services: public relations, 202202 service existent by MC Services 2022-02-09
Lindis Blood Care–OTHER: investment, 202202 follow-on financing round incl several private investors 2022-02-09
Lindis Blood Care–SEVERAL: investment, 202202 follow-on financing round led by HTGF + Brandenburg Kapital + several private investors 2022-02-09
Protix–ECBF: investment, 202202 financing round totalling €50m incl investor ECBF 2022-02-09
Protix–SEVERAL: investment, 202202 financing round €50m from ECBF + BNP Paribas et al 2022-02-09
Formo–BRAIN Biotech: genome editing technology, 202202– collab using CRISPR BEC platform to scale production of bioidentical milk protein 2022-02-08
In-Part–Inova Software: investment, 202202 acquisition of In-Part by Inova 2022-02-08
Elicit Plant–ECBF: investment, 202202 equity component €na of €16m funding round incl co-investor ECBF 2022-02-07
Elicit Plant–SEVERAL: investment, 202202 equity component €na led by Sofinnova Partners as part of funding round totalling €16m 2022-02-07
iOmx Therapeutics–MC Services: public relations, 202202 service existent by MC Services 2022-02-03
Merck (DE)–eTheRNA: mRNA technology, 202202– collab research using eTheRNA’s mRNA + LNP technologies to evaluate therapeutic feasibility 2022-02-03
Nemis Technologies–SEVERAL: investment, 202202 financing round Series A CHF7.75m from institutional + private investors 2022-02-03
Weriol Group–BRAIN Biotech: investment, 202202 acquisition of 62% of Breatec/Comix for €3.7m upfront + option to acquire remaining shares until 2027Q1 2022-02-03
Ethris–Laureus Capital: investment, 202201 financing round Series B totalling €23.3m inc lead investor Laureus Capital 2022-02-01
Ethris–SEVERAL: investment, 202201 financing round Series B €23.3m led by Laureus Capital 2022-02-01
Ethris–Trophic Communications: public relations, 202201 service existent by Trophic 2022-02-01
Glycotope–Canton Biologics: investment, 202201 acquisition of newly formed FyoniBio GmbH from Glycotope by CantonBio Deutschland GmbH 2022-02-01
myPOLS Biotec–Medix Biochemica: investment, 202202 acquisition 100% of myPOLS Biotec GmbH by Medix Biochemica 2022-02-01
Noventi–Temedica: healthcare data analytics, 202202– collab using Permea system to advance healthcare research with real-world data 2022-02-01
Pharvaris–BRAIN Biotech: drug discovery services, 202202–202307 collab extension 9 months RnD bradykinin-B2-receptor antagonists Analyticon Discovery 2022-02-01
Zetta Genomics–SEVERAL: investment, 202202 seed financing round £2.5m with Cambridge Enterprise + Apex Ventures + Nina Capital 2022-02-01
Gandeeva Therapeutics–Bayer: investment, 202201 financing round Series A totalling $40m incl co-lead investor Leaps by Bayer 2022-01-31
Gandeeva Therapeutics–SEVERAL: investment, 202201 financing round Series A $40m led by Lux Capital + Leaps by Bayer 2022-01-31
Ribbon Biolabs–SEVERAL: investment, 202201 financing round Series A €18m led by Hadean Ventures 2022-01-31
Ribbon Biolabs–Trophic Communications: public relations, 202201 service existent by Trophic 2022-01-31
xbird–Glooko: investment, 202201 acquisition of xbird GmbH by Glooko Inc 2022-01-31
Mainz Biomed–SEVERAL: investment, 202201 public follow-on offering $22.5m+$3.375m with 1.725m+225k common shares at $15/share 2022-01-28
Cellino–Bayer: investment, 202201 financing round Series A totalling $80m incl new + lead investor Leaps by Bayer 2022-01-25
Cellino–SEVERAL: investment, 202201 financing round Series A $80m led by Leaps by Bayer + 8VC + Humboldt Fund 2022-01-25
Cytovation–SEVERAL: investment, 202201 financing round Series A NOK180m (€20m) led by Sandwater + Canica 2022-01-25
InstaDeep–BioNTech: investment, 202201 financing round Series B totalling $100m incl co-investor BioNTech 2022-01-25
InstaDeep–SEVERAL: investment, 202201 financing round Series B $100m led by Alpha Intelligence Capital with CDIB 2022-01-25
Metagenomi–Bayer: investment, 202201 financing round Series B totalling $175m incl existing + co-investor Leaps by Bayer 2022-01-25
Metagenomi–SEVERAL: investment, 202201 financing round Series B $175m co-led by PFM Health Sciences + Farallon Capital Mgt + NN 2022-01-25
Ferring–Cyprumed: drug delivery technology, 202201– collab expansion RnD for oral drug delivery of peptide therapeutics 2022-01-24
Elastrin Therapeutics–Forever Healthy: investment, 202201 existent investment of Kizoo 2022-01-21
Lift BioSciences–Forever Healthy: investment, 202201 financing round totalling £5m incl existing + co-investor Kizoo Technology Ventures 2022-01-21
Lift BioSciences–SEVERAL: investment, 202201 financing round £5m led by new investor Starbloom Capital 2022-01-21
Revel Pharmaceuticals–Forever Healthy: investment, 202201 existent investment of Kizoo 2022-01-21
Underdog–Forever Healthy: investment, 202201 existent investment of Kizoo 2022-01-21
Prolab Instruments–Bruker: investment, 202201 acquisition €na of Prolab Instruments Gmbh by Bruker 2022-01-19
Labiotech.eu–Inova Software: investment, 202201 acquisition by Inova 2022-01-18
PreOmics–Bruker: investment, 202201 acquisition €na of shares of HTGF + Think.Health Ventures + certain business angels by Bruker 2022-01-18
PreOmics–Bruker: investment, 202201 Series B investment €13.5m from Bruker tog w secondary transaction making Bruker majority shareholder 2022-01-18
Indivumed–EU (govt): grant, 202201– funding €4.3m from ERDF Structural Fund REACT-EU programme for personalised cancer drug development 2022-01-17
ProtaGene–Ampersand: investment, 202201 existent portfolio company after merger/acquisition of PPS GmbH + BioAnalytix + GeneWerk GmbH in 7/21 2022-01-12
Temedica–MC Services: public relations, 202201 service existent PR + IR by MC Services 2022-01-12
Biosyntia–Wacker: biotin, 202201–collab developm of large-scale biotin production process based on sustainable fermentation 2022-01-11
Creoptix–Spectris: investment, 202201 acquisition of Creoptix AG by Malvern Panalytical 2022-01-11
Pantherna Therapeutics–High-Tech Gründerfonds: investment, 202201 follow-on financing round totalling €4m incl existing + co-lead investor HTGF 2022-01-11
Pantherna Therapeutics–PERSON: investment, 202201 follow-on financing round totalling €4m incl existing + co-lead investor Riesner Verwaltungs GmbH 2022-01-11
Pantherna Therapeutics–SEVERAL: investment, 202201 follow-on financing round €4m led by existing investors Detlev Riesner + HTGF 2022-01-11
BioNTech–Crescendo Biologics: antibody technology, 202201–202512 collab ww up to $790m + royalties using Humabody VH platform for BioNTech targets 2022-01-10
Crescendo Biologics–BioNTech: investment, 202201 equity investment €na as part of €40m collab upfront payment with cash + equity investment 2022-01-10
Exelead–Merck (DE): investment, 202201 acquisition $760m in cash by Merck 2022-01-06
BioNTech–Pfizer: investment, 202201 equity investment $150m by Pfizer in connection with shingles vaccine collaboration 2022-01-05
Pfizer–BioNTech: mRNA-based vaccines, 202201– collab developm $50m net cash upfront shingles vaccine with shared development cost + profits 2022-01-05
ALS Automated Lab Solutions–Sartorius: investment, 202201–2026 acquisition of 62.5% share in ALS with remaining share to be acquired in 2026 2022-01-03
Evolva–Nice & Green: credit, 202112–202312 convertible notes financing with incremental lines up to max of CHF12m principal amount 2021-12-27
Grand Pharma–ITM: radiopharmaceutical, 202112– license excl dev + production + commerc of ITM-11 + ITM-41 + TOCscan in Greater China 2021-12-27
Gyroscope Therapeutics–Novartis: investment, 202112– acquisition $800m upfront + $700m milestones by Novartis ANNOUNCED 2021-12-22
Thuja Capital–SEVERAL: investment, 202112 final closing of Thuja Capital Heathcare Fund III at €76m incl investor EIF 2021-12-21
Chord Therapeutics–Merck (DE): investment, 202112– acquisition of Chord by Merck KGaA from sole investor Omega Funds 2021-12-20
Anaveon–Cowen: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Cowen Healthcare Investments 2021-12-16
Anaveon–Forbion: investment, 202112 financing round Series B totalling CHF110m incl new + lead investor Forbion 2021-12-16
Anaveon–JW Communications: public relations, 202112 service existent by JW Communications 2021-12-16
Anaveon–Novartis: investment, 202112 financing round Series B totalling CHF110m incl existing + co-investor Novartis Venture Fund 2021-12-16
Anaveon–Pfizer: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pifzer Ventures 2021-12-16
Anaveon–Pontifax: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pontifax 2021-12-16
Anaveon–SEVERAL: investment, 202112 financing round Series B CHF110m with new + lead investor Forbion 2021-12-16
Anaveon–Syncona: investment, 202112 financing round Series B totalling CHF110m incl existing + co-lead investor Syncona 2021-12-16
Brainomix–Boehringer: investment, 202112 financing round Series B totalling £16m incl existing + co-lead investor BIVF 2021-12-16
Brainomix–SEVERAL: investment, 202112 financing round Series B £16m co-led by existing investors BIVF + Parkwalk Advisors 2021-12-16
Evotec–Gates Foundation: grant, 202112– grant $18m for drug r+d in area of women’s health + contraceptive technology 2021-12-16
Patronus Health–Hessen (govt): grant, 202112 public grant from State of Hesse 2021-12-16
Patronus Health–MC Services: public relations, 202112 service existent by MC Services 2021-12-16
Patronus Health–SEVERAL: investment, 202112 pre-seed financing round led by business angel Georg Matheis 2021-12-16
Lonza–Agilent: analytical instruments, 202112– strategic alliance to integrate analytical technologies in Cocoon cell therapy production platform 2021-12-15
BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme 2021-12-14
Novartis–Molecular Partners: DARPins, 202112– collab $20m upfront + $560m milestones + royalties license to develop + manuf + commerc DARPin-RLTs 2021-12-14
Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED 2021-12-14
Memo Therapeutics–Switzerland (govt): grant, 202112– FOPH grant CHF10.5m for clinical developm of SARS-CoV-2 antibody COVAB 36 2021-12-13
deepCDR Biologics–Alloy Therapeutics: investment, 202112 acquisition of deepCDR Biologics by Alloy 2021-12-09
Forbion European Acquisition Corporation–SEVERAL: investment, 202112 SPAC US IPO $110m with 11m units at $10/unit 2021-12-09
Aleph Farms–Wacker: cell culture media, 202112– collab developm production process for growth-medium proteins for cultured meat 2021-12-08
Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures 2021-12-08
Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital 2021-12-07
next pagenext page 1 2 3 4 5 6 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top